Metastatic CRC participants with the WT TLR4 allele had higher PFS (hazard ratio (HR): 0.73; 95% confidence interval (CI) = 0.53–1.00; P < 0.05) and OS (HR = 0.72; 95% CI = 0.52–1.01; P = 0.05) compared with participants bearing the TLR4 loss-of-function (Asp299Gly) variant post-oxaliplatin chemotherapy treatment (Tesniere et al. 2010). This evidence concerns the gene TLR4 and colorectal carcinoma.